effect overlay
activetrials
Multiple sclerosis
Multiple Sclerosis
FiRMS EBV

Fatigue in Relapsing Multiple Sclerosis Epstein Barr Virus Treatment Trial – FiRMS EBV

HREC: 2024.137
Principal Investigator: Dr Izanne Roos
Coordinator contact: Katherine Fazzolari
Funding: Non-Commercial
Active Trials - Other
Huntington's Disease
Skyhawk HD Phase 2

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

HREC: 2025.141
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Anice Abin & Lei Chen
Funding: Commercial
Stroke
Stroke
LOTUS

LOw dose combinations To improve stroke oUtcomeS (LOTUS)

HREC: 2025.053
Principal Investigator: Prof Bruce Campbell
Coordinator contact: Christine Shin
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
RESHAPE

CLOU064C12306: A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib

HREC: 2025.026
Principal Investigator: Dr Ai-Lan Nguyen
Coordinator contact: Katherine Fazzolari
Funding: Commercial
Stroke
Stroke
ACT GLOBAL

A multi-faCtorial, mulTi-arm, multi-staGe, randomised, gLOBal pLatform trial for Stroke (ACT-GLOBAL)

HREC: 2025.024
Principal Investigator: Prof Bruce Campbell
Coordinator contact: David Jackson
Funding: Non-Commercial